GENE ONLINE|News &
Opinion
Blog

Hemophilia A
FDA Approves Sanofi and Sobi’s Once-Weekly Hemophilia A Med
2023-02-23
Pfizer, Sangamo Re-Opens Enrolment For Hemophilia A Gene Therapy
2022-09-26
Sanofi’s Treatment for Hemophilia A has a Concrete FDA Decision Date
2022-08-30
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
Pfizer, Sangamo Dose First Hemophilia A Patient in Phase 3 with Gene Therapy Candidate
2020-10-08
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
Sangamo’s Shares Goes up after the Announcement of Investigational Hemophilia A Gene Therapy Results
2019-07-19
Emicizumab promises weekly/biweekly prophylaxis in hemophilia-A patients
2018-09-04
LATEST
Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
2023-12-06
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
2023-12-05
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
2023-12-05
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
Unveiling the Role of Microbes in Climate Change at COP28
2023-12-04
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
EVENT
Scroll to Top